Zacks Investment Research
08 Jul 2026, 15:40 UTC · 11w ago
Verdict
Headline takes no side. We score XERS +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Xeris Biopharma (XERS) is expected to report a year-over-year quarterly earnings increase of 300% to $0.02 per share.
More positive than 93% of claims this week
Xeris Biopharma (XERS) revenues for the upcoming quarter are projected to increase 26.8% year-over-year to $90.73 million.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 79% of claims this week
Xeris Biopharma (XERS) shares rose 6.8% in the last session on above-average volume, contributing to a 34.1% gain over four weeks.
More positive than 66% of claims this week
The consensus EPS estimate for Xeris Biopharma has remained unchanged over the last 30 days.
More negative than 69% of claims this week
Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+9.1%
Price agrees with the score
$9.76 vs $8.94 close before publication (Jul 7) · not market-adjusted
XERS chart →
